Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal) (TA270)
NICE is unable to make a recommendation about the use in the NHS of decitabine for the treatment of acute myeloid leukaemia because no evidence...
Search results
1425 results
-
-
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284)
Evidence-based recommendations on bevacizumab (Avastin) in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
-
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)
Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia
-
Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) (TA564)
NICE is unable to make a recommendation about the use in the NHS of dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive
-
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) (TA568)
NICE is unable to make a recommendation on abatacept (Orencia) for treating psoriatic arthritis after DMARDs in adults because of no evidence submission from
-
Decitabine for untreated acute myeloid leukaemia (terminated appraisal) (TA548)
NICE is unable to make a recommendation about the use in the NHS of decitabine for untreated acute myeloid leukaemia because no evidence submission was
-
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) (TA549)
NICE is unable to make a recommendation about the use in the NHS of denosumab for preventing skeletal-related events in multiple myeloma because no evidence
-
Guidance on the use of paclitaxel in the treatment of ovarian cancer (TA55)
Evidence-based recommendations on paclitaxel for treating ovarian cancer in adults
-
Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) (TA582)
NICE is unable to make a recommendation about the use in the NHS of cabozantinib (Cometriq) for previously treated advanced hepatocellular carcinoma in adults
-
Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) (TA576)
NICE is unable to make a recommendation about the use in the NHS of bosutinib for untreated chronic myeloid leukaemia because no evidence submission was
-
Padeliporfin for untreated localised prostate cancer (TA546)
Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults
-
Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)
Evidence-based recommendations on filgotinib (Jyseleca) for moderate to severe rheumatoid arthritis in adults
-
Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA678)
NICE is unable to make a recommendation on omalizumab (Xolair) for treating chronic rhinosinusitis with nasal polyps in adults because Novartis Pharmaceuticals
-
Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)
Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults
-
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) (TA570)
NICE is unable to make a recommendation about the use in the NHS of pembrolizumab (Keytruda) for treating recurrent or metastatic squamous cell carcinoma of the
-
Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma (TA677)
Evidence-based recommendations on autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma in adults who have
-
Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)
Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma (tumours/cancer)
-
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (TA673)
Evidence-based recommendations on niraparib for maintenance treatment of advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary
-
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) (TA674)
NICE is unable to make a recommendation on pembrolizumab (Keytruda) for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when
-
Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal) (TA675)
NICE is unable to make a recommendation on vernakalant (Brinavess) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. This
-
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632)
Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in adults who
-
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (TA639)
Evidence-based recommendations on atezolizumab (Tecentriq) with nab-paclitaxel for triple-negative, unresectable, PD-L1-positive, locally advanced or metastatic
-
Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block (TA88)
Evidence-based recommendations on dual-chamber pacemakers for symptomatic bradycardia (slow heart rate) due to sick sinus syndrome and/or atrioventricular block
-
Immunosuppressive therapy for kidney transplant in adults (TA481)
Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in adults
-
Tofacitinib for moderate to severe rheumatoid arthritis (TA480)
Evidence-based recommendations on tofacitinib (Xeljanz) for treating moderate to severe rheumatoid arthritis (rheumatism) in adults
-
Reslizumab for treating severe eosinophilic asthma (TA479)
Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults
-
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults
-
Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (TA477)
Evidence-based recommendations on autologous chondrocyte implantation (ACI) in people with symptomatic articular cartilage defects of the knee
-
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (TA476)
Evidence-based recommendations on paclitaxel as albumin-bound nanoparticles (nab-paclitaxel; Abraxane) for untreated metastatic pancreatic cancer in adults
-
Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)
Evidence-based recommendations on dimethyl fumarate (Skilarence) for treating moderate to severe plaque psoriasis in adults
-
Sorafenib for treating advanced hepatocellular carcinoma (TA474)
Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma (liver cancer) in adults
-
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)
Evidence-based recommendations on cetuximab (Erbitux) for treating recurrent or metastatic squamous cell cancer of the head and neck in adults
-
Eluxadoline for treating irritable bowel syndrome with diarrhoea (TA471)
Evidence-based recommendations on eluxadoline (Truberzi) for treating irritable bowel syndrome (IBS) with diarrhoea in adults
-
Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) (TA469)
NICE is unable to make a recommendation about the use in the NHS of idelalisib with ofatumumab for treating chronic lymphocytic leukaemia because no evidence
-
Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) (TA468)
NICE was unable to make a recommendation about the use in the NHS of methylnaltrexone bromide for treating opioid-induced constipation because no evidence was
-
Baricitinib for moderate to severe rheumatoid arthritis (TA466)
Evidence-based recommendations on baricitinib (Olumiant) for moderate to severe rheumatoid arthritis in adults
-
Bisphosphonates for treating osteoporosis (TA464)
Evidence-based recommendations on the bisphosphonates alendronic acid, ibandronic acid, risedronate sodium and zoledronic acid for treating osteoporosis
-
Cabozantinib for previously treated advanced renal cell carcinoma (TA463)
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma (kidney cancer) in adults
-
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)
Evidence-based recommendations on nivolumab (Opdivo) for treating relapsed or refractory classical Hodgkin lymphoma in adults
-
Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)
Evidence-based recommendations on lenvatinib (Kisplyx) with everolimus for previously treated advanced renal cell carcinoma (kidney cancer) in adults
-
Golimumab for treating non-radiographic axial spondyloarthritis (TA497)
Evidence-based recommendations on golimumab (Simponi) for severe non-radiographic axial spondyloarthritis in adults
-
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)
Evidence-based recommendations on ribociclib (Kisqali) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor
-
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)
Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone receptor-positive, HER2-negative, locally advanced or
-
Naltrexone–bupropion for managing overweight and obesity (TA494)
Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults
-
Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)
Evidence-based recommendations on atezolizumab (Tecentriq) for untreated PD-L1-positive locally advanced or metastatic urothelial carcinoma in adults
-
Ibrutinib for treating Waldenstrom's macroglobulinaemia (TA491)
Evidence-based recommendations on ibrutinib (Imbruvica) for treating Waldenstrom's macroglobulinaemia (non-Hodgkin lymphoma) in adults after at least 1 therapy
-
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA490)
Evidence-based recommendations on nivolumab (Opdivo) for squamous cell carcinoma of the head and neck in adults
-
Vismodegib for treating basal cell carcinoma (TA489)
Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma (BCC; non-melanoma skin cancer; rodent ulcers) in adults
-
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)
Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults
-
Venetoclax for treating chronic lymphocytic leukaemia (TA487)
Evidence-based recommendations on venetoclax (Venclyxto) for treating chronic lymphocytic leukaemia in adults